AHRQ Research Priorities Should Include Quality Of Cardiovascular Care, Guidant Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency should research a potential disparity in cardiovascular care between men and women, and the clinical and economic benefits of early screening for carotid artery disease, Guidant says. The device industry has also raised new technology underutilization and e-health as potential topics.
You may also be interested in...
Pfizer, Novartis Learning The VALUE Of Comparative Research
Novartis-sponsored trial of Diovan vs. Norvasc finds no difference in cardiac morbidity and mortality. Norvasc shows better blood pressure control and fewer heart attacks, although Novartis is touting Diovan's reduction of diabetes onset. Study is the second comparative trial in recent months in which competitor-sponsored data show an advantage for Pfizer's products.
Pfizer, Novartis Learning The VALUE Of Comparative Research
Novartis-sponsored trial of Diovan vs. Norvasc finds no difference in cardiac morbidity and mortality. Norvasc shows better blood pressure control and fewer heart attacks, although Novartis is touting Diovan's reduction of diabetes onset. Study is the second comparative trial in recent months in which competitor-sponsored data show an advantage for Pfizer's products.
AHRQ Rx Comparisons Should Focus On Existing Literature, Not Clinical Trials, McClellan Says
Clinical trials take too much time and money, CMS Administrator McClellan says. Programs mandated under Medicare Rx law, such as the chronic care improvement pilot and the Part B replacement drug demo, will provide clinical data to evaluate comparative effectiveness, he says.